Apellis Pharmaceuticals Inc. Reports Q1 2025 Earnings
Apellis Pharmaceuticals, Inc. (APLS), a clinical-stage biopharmaceutical company specializing in autoimmune and inflammatory diseases, recently disclosed its Q1 2025 earnings. The company, based in Waltham, United States, operates globally within the biotechnology sector of the health care industry.
Earnings Overview
In its Q1 2025 earnings call, Apellis reported a GAAP earnings per share (EPS) of -$0.74, which fell short of expectations by $0.39. Additionally, the company’s revenue for the quarter was $166.8 million, missing the anticipated figure by $28.08 million. These results reflect the challenges faced by the company in achieving its financial targets for the period.
Stock Performance and Market Data
As of May 4, 2025, Apellis Pharmaceuticals’ stock closed at $19.98. The company’s 52-week high was recorded at $43.99 on May 21, 2024, while the 52-week low stood at $16.975 as of April 24, 2025. The market capitalization of Apellis Pharmaceuticals is currently valued at $2.52 billion. The price-to-earnings ratio is reported at -12.56, indicating the company’s current earnings challenges.
Upcoming Investor Conferences
In addition to the earnings report, Apellis Pharmaceuticals announced its participation in several upcoming investor conferences. The company will engage in a fireside chat at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:40 a.m. PT. Additionally, Apellis will participate in the Stifel 2025 Virtual Ophthalmology Forum with a fireside chat scheduled for Tuesday, May 27, 2025, at 2:30 p.m. ET. These events provide an opportunity for Apellis to discuss its strategic direction and future prospects with investors and analysts.
Conclusion
Apellis Pharmaceuticals continues to focus on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Despite the recent earnings miss, the company remains committed to advancing its pipeline and engaging with the investment community through upcoming conferences.